Business Description
Advagene Biopharma Co Ltd
ISIN : TW0006709009
Share Class Description:
ROCO:6709: Ordinary SharesDescription
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 143.9 | |||||
| Equity-to-Asset | 0.95 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -4.6 | |||||
| 3-Year EPS without NRI Growth Rate | -5.3 | |||||
| 3-Year FCF Growth Rate | -29.9 | |||||
| 3-Year Book Growth Rate | -26.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.15 | |||||
| 9-Day RSI | 52.32 | |||||
| 14-Day RSI | 54.85 | |||||
| 6-1 Month Momentum % | -28.6 | |||||
| 12-1 Month Momentum % | -36.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 18.37 | |||||
| Quick Ratio | 18.37 | |||||
| Cash Ratio | 15.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.9 | |||||
| Shareholder Yield % | 0.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -77.43 | |||||
| ROA % | -72.21 | |||||
| ROIC % | -386.54 | |||||
| ROC (Joel Greenblatt) % | -550.93 | |||||
| ROCE % | -77.26 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 8.99 | |||||
| Price-to-Tangible-Book | 8.99 | |||||
| EV-to-EBIT | -12.3 | |||||
| EV-to-EBITDA | -14.14 | |||||
| EV-to-FCF | -16.92 | |||||
| Price-to-Net-Current-Asset-Value | 9.09 | |||||
| Price-to-Net-Cash | 10.7 | |||||
| Earnings Yield (Greenblatt) % | -8.13 | |||||
| FCF Yield % | -6.18 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Advagene Biopharma Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | |||
| EPS (TTM) (NT$) | -1.83 | ||
| Beta | -0.01 | ||
| Volatility % | 40.12 | ||
| 14-Day RSI | 54.85 | ||
| 14-Day ATR (NT$) | 1.76868 | ||
| 20-Day SMA (NT$) | 21.815 | ||
| 12-1 Month Momentum % | -36.6 | ||
| 52-Week Range (NT$) | 16.4 - 32.654526 | ||
| Shares Outstanding (Mil) | 53.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Advagene Biopharma Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Advagene Biopharma Co Ltd Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Advagene Biopharma Co Ltd Frequently Asked Questions
What is Advagene Biopharma Co Ltd(ROCO:6709)'s stock price today?
The current price of ROCO:6709 is NT$23.55. The 52 week high of ROCO:6709 is NT$32.65 and 52 week low is NT$16.40.
When is next earnings date of Advagene Biopharma Co Ltd(ROCO:6709)?
The next earnings date of Advagene Biopharma Co Ltd(ROCO:6709) is .
Does Advagene Biopharma Co Ltd(ROCO:6709) pay dividends? If so, how much?
Advagene Biopharma Co Ltd(ROCO:6709) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers